One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine (Plaquenil), a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine fda pregnancy category Chloroquine for lung cancer This article is from June 2011 and may contain outdated material. Download PDF. Many systemic medications may cause retinal toxicity. One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine Plaquenil, a chloroquine derivative. Hydroxychloroquine Plaquenil is used to treat malaria, lupus, and rheumatoid arthritis. Learn about side effects, warnings, dosage, and more. Hydroxychloroquine Plaquenil is considered a disease-modifying anti-rheumatic drug DMARD. It can decrease the pain and swelling of arthritis. It may prevent joint damage and reduce the risk of long-term disability. Hydroxychloroquine is in a class of medications that was first used to prevent and treat malaria. It is imperative that patients and physicians are aware of and watch for this drug’s ocular side effects. Retinal toxicity from hydroxychloroquine is rare, but even if the medication is discontinued, vision loss may be irreversible and may continue to progress. Plaquenil premaculopathy Hydroxychloroquine-Induced Retinal Toxicity - American Academy of., Hydroxychloroquine Side Effects, Dosage, Uses, and More Plaquenil birth control affects The American Academy of Ophthalmology released an updated set of screening recommendations for hydroxychloroquine Plaquenil and chloroquine to account for the many studies that have shown the effects of these medications on the retina 1. It succinctly makes the case for screening, and Hydroxychloroquine And Chloroquine Screening 2016 AAO Recommendations.. Hydroxychloroquine Plaquenil. Hydroxychloroquine Plaquenil Toxicity and.. Plaquenil is the brand name for the prescription drug hydroxychloroquine. It's used to treat and prevent malaria infection, and to reduce symptoms and progression of autoimmune diseases such as lupus, rheumatoid arthritis, and others. Hydroxychloroquine Retinopathy - Premaculopathy, part B This 46 year old woman with systemic lupus erythematosus had taken HC for 7 years at 400 mg/d and stopped because of inadequate response. Three years later she was interested in restarting the drug and was seen for clearance. Dr. Marmor’s research team also recommended that screening should be performed within the first year of initiating therapy, and then annually after five years of Plaquenil use. The risk for retinal toxicity begins once the patient has used Plaquenil for five to seven years and/or has taken a cumulative dose of more than 1,000g.